Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012)

• Published in: Veterinary & comparative oncology Vol. 14; no. S1; pp. 136 - 146
• Main Authors: Collette, S. A., Allstadt, S. D., Chon, E. M., Vernau, W., Smith, A. N., Garrett, L. D., Choy, K., Rebhun, R. B., Rodriguez Jr, C. O., Skorupski, K. A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.08.2016
• Subjects: Animals; Antibiotics, Antineoplastic - pharmacology; Antineoplastic Agents - pharmacology; Antineoplastic Agents, Alkylating - pharmacology; Antineoplastic Combined Chemotherapy Protocols - pharmacology; cat; Cat Diseases - drug therapy; Cats; CHOP; Cyclophosphamide - pharmacology; Doxorubicin - pharmacology; feline; Female; Kaplan-Meier Estimate; lymphoma; Lymphoma, Non-Hodgkin - drug therapy; Lymphoma, Non-Hodgkin - veterinary; maintenance-free chemotherapy; Male; Medical Records; Prednisone - pharmacology; Prognosis; Schools, Veterinary; survival; Survival Analysis; Treatment Outcome; United States; Vinca Alkaloids - pharmacology; Vincristine - pharmacology; CHOP; feline; maintenance-free chemotherapy; cat; lymphoma; survival
• ISSN: 1476-5810; 1476-5829
• DOI: 10.1111/vco.12158

CHOP‐based (cyclophosphamide, doxorubicin, vinca alkaloid, prednisolone) chemotherapy protocols are often recommended for treatment of feline lymphoma. While maintenance‐free CHOP‐based protocols have been published and readily used in dogs, there is limited literature regarding similar maintenance‐free protocols in cats. The purpose of this study was to describe the outcome of cats with intermediate‐ to high‐grade lymphoma that were prescribed a modified 25‐week University of Wisconsin–Madison (UW‐25) chemotherapy protocol. A secondary objective was examination of potential prognostic factors. One hundred and nineteen cats from five institutions treated with a UW‐25‐based protocol were included. The Kaplan–Meier median progression‐free interval (PFI) and survival time (MST) were 56 and 97 (range 2–2019) days, respectively. Cats assessed as having a complete response (CR) to therapy had significantly longer PFI and MST than those with partial or no response (PFI 205 versus 54 versus 21 days, respectively, P < 0.0001 and MST 318 versus 85 versus 27 days, respectively, P < 0.0001).